Flow and tDCS Evidence Flow Overview Flow Webinars In-clinic Resources Marketing Materials

Flow and tDCS Evidence Flow Overview Flow Webinars In-clinic Resources Marketing Materials

Flow & tDCS Evidence

Data Pack front cover

Flow Neuroscience

Nov, 2023

Summary of Flow evidence including safety, efficacy, and side effect information

NHS Journal of Depression CMHT

Griffiths, C. , Walker, K. , Willis, A.

Feb, 2024

Qualitative Study Exploring the Experience and Value of Flow - Community Mental Health

NICE MIB324

National Institute of Care Excellence

Nov, 2023

NICE Medical Innovation Briefing (MIB324) on Flow Neuroscience

NHS Journal of Depression GP

Griffiths, C. , Walker, K. , Jiang, H. , Noel-Johnson, A. and Zafar, A.

Nov, 2023

Qualitative Study Exploring the Experience and Value of Flow - Primary Care

Additional studies showcasing Flow

Flow RCT

Home-based tDCS is a potential first line treatment for MDD that is acceptable and safe

Ganho Ávila1 et al. 2022

Using Flow home-based tDCS in clinical practice; case series

Woodham et al. 2022

Is Flow a potential first line of treatment for depression?

Additional studies reviewing tDCS

tDCS antidepressant effects peak at 6 weeks

tDCS antidepressant effects peak at around 6 weeks

Frengi et al. 2021

tDCS for depression is definitely effective (level A evidence)

Moffa et al. 2020

A meta-analysis: tDCS was an effective intervention in reducing depressive symptoms